Who owns INSM? 13F holders and whale ownership
INSM is tracked across public portfolios in Whale Analyzer. This page answers who owns INSM, which top funds are buying INSM, aggregate disclosed value, and recent position changes based on public data. Baker Bros. Advisors is the largest reported holder at $1.21B; the top five funds control 100.0% of reported ownership; institutions were net buying last quarter (2 increased, 1 reduced); the stock trades below the aggregate whale cost basis of $149.33. Top tracked holders include Baker Bros. Advisors, Stanley Druckenmiller, and Ray Dalio.
Continue to the live INSM dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $1.21B | 7.4M | Increased |
| Stanley Druckenmiller 13F portfolio Duquesne Family Office holdings | $188.7M | 1.2M | Reduced |
| Ray Dalio 13F portfolio Bridgewater Associates holdings | $48.3M | 295.6K | New |
Ownership concentration
Reported ownership of INSM is highly concentrated across tracked institutions.
- Single largest holder: 83.7% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 3 tracked institutions, 2 increased, 1 reduced. Net positioning is net buying.
- Baker Bros. Advisors — Baker Bros. Advisors ($1.21B) (▲ 12.6% qoq shares)
- Stanley Druckenmiller — Duquesne Family Office ($188.7M) (▼ 22.1% qoq shares)
- Ray Dalio — Bridgewater Associates ($48.3M) · avg cost $149.33
Whale cost basis vs current price
The aggregate tracked cost basis is $149.33 versus a current price of $103.38, so INSM trades below its cost basis (-30.8%). Average unrealized P&L across tracked holders: -28%.
Sector positioning — Health Care
INSM sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live INSM dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- INCY whale holders — Incyte Corporation
- BEIGF whale holders — BeOne Medicines Ltd.
- MDGL whale holders — Madrigal Pharmaceuticals, Inc.
- ACAD whale holders — ACADIA Pharmaceuticals Inc.
- RVMDW whale holders — Revolution Medicines, Inc.
- CELC whale holders — Celcuity Inc.
- KOD whale holders — Kodiak Sciences Inc.
- KYMR whale holders — Kymera Therapeutics, Inc.
Learn more in Whale Analyzer Academy
Deepen your read on INSM with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns INSM stock?
Whale Analyzer tracks 3 public institutional holders of INSM with a combined reported value of $1.45B. See the holder table above for the largest tracked positions.
Which top funds are buying INSM?
Tracked institutions were net buying last quarter — 2 increased, 1 reduced. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is INSM ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is INSM above or below the whale cost basis?
The aggregate tracked cost basis is $149.33 versus a current price of $103.38 (-30.8%).
What does 13F ownership mean for INSM?
Use the interactive INSM dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.